menu
    • menu
    [{"orgOrder":0,"company":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Colchicine","moa":"Beta Tubulin Polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Extended-Release Tablet","sponsorNew":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC \/ Pendopharm","highestDevelopmentStatusID":"12","companyTruncated":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC \/ Pendopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

    Menu

    PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Montreal Heart Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study

                            Details : Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

                            Brand Name : Myinfla

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 27, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Montreal Heart Institute

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth